Counterfeiting is Killing.

Counterfeit medicines kill up to 300,000 children each year.

For decades, compliance was treated as a bureaucratic exercise in producing static evidence. Organizations relied on spreadsheets, PDFs, and batch reports generated long after the fact, operating under a model that assumed trust first and verification second. This traditional framing treats counterfeiting as a mere commercial nuisance. It is viewed as a secondary concern that hurts margins, brand equity, or tax revenue. However, that perspective misses the lethal reality occurring on the ground where fakes are infiltrating legitimate supply chains and people young and old are dying.

Lethal counterfeit medicines are no longer confined to black markets or suspicious websites because they have entered authorized distribution channels. The recent surge in counterfeit Ozempic and other semaglutide products has highlighted this crisis, with the World Health Organization issuing global alerts after fakes were discovered in the legitimate supply chains of the United Kingdom, Brazil, and the United States.

High profile instances of counterfeit medicines identified within legitimate supply chains include:

• Counterfeit Ozempic: Three counterfeit batches were discovered in late 2023 in Brazil, the United Kingdom, and the United States, appearing in legitimate supply chains.
• Insulin Substitution: European health regulators reported that several people suffered from severe hypoglycemia after taking suspected fake Ozempic that likely contained insulin instead of semaglutide.
• Pediatric Syrups: In 2022, over 300 child deaths in The Gambia, Indonesia, and Uzbekistan were linked to cough syrups contaminated with toxic levels of diethylene glycol and ethylene glycol.
• Unauthorized Distribution: The FDA seized dozens of counterfeit Ozempic units in late 2025 that were distributed outside of the authorized supply chain but found within the legitimate U.S. drug supply.
• Fentanyl Laced Pharmaceuticals: The DEA has reported a sharp increase in the lethality of fake prescription pills laced with fentanyl, often made to look identical to real medications like OxyContin, Percocet, and Xanax. In 2022, six out of ten fentanyl-laced fake pills analyzed contained a potentially lethal dose.

The striking factor is not just the harm caused, but the convincing nature of these products. The packaging passes visual inspection, labels are professional, and the documentation exists. On paper, everything appeared compliant because most current systems are designed to produce paper rather than prove reality. Global trade relies on a fragmented architecture of passed trust. When a product moves from a manufacturer to a distributor, and then to a regional warehouse, each handoff relies on a digital or physical attestation. If that attestation is forged at any point, the error propagates through the rest of the chain.

Modern supply chains move too fast and stretch too far for these traditional controls to maintain integrity. A product can pass through multiple countries, vendors, and warehouses, with each handoff creating a blind spot. Once a counterfeit enters this flow, it blends in seamlessly. Batch level tracking is ineffective when the threat is a specific item, and supplier attestations fail when the breach happens downstream. Traditional inspections occur too late. By the time a product triggers an investigation, it has already been consumed. Counterfeiters are winning not because they are more sophisticated, but because the systems intended to stop them are still built around trust, reporting, and hindsight. Regulators and auditors are realizing that a policy does not prove behavior, a disclosure does not prove authenticity, and a compliance report does not prove that a specific item followed a controlled path. When authenticity cannot be proven at the item level, risk becomes uncontainable and counterfeits become a statistical certainty.

SOLUTION

The only way to stop counterfeits before they cause harm is to abandon reliance on after the fact explanations and begin generating evidence as products move. This requires a fundamental shift from visibility to proof. Real protection is found in the ability to answer simple questions with absolute certainty. We must know where this specific item originated, how it moved, who handled it, and if it deviated from the approved path.

Our approach enables item level traceability through a structured implementation process:

• Establish Unique Identification: Every physical unit is assigned a data-filled, unique identifier via Duel Frequency NFC/RFID tags that serve as its digital fingerprints.
• Digital Twin Creation: A virtual replica, or digital twin, is generated for every individual item, mirroring its real-world characteristics and performance throughout its lifecycle.
• Real-Time Data Integration: Using IoT sensors and automated scanning, the system captures transaction-level facts, including geolocation, timestamps, and facility IDs, as they happen.
• Automated Verification (No Encode Workflow): Workflows are standardized to capture evidence silently within existing operations, allowing for rapid inventory reporting without manual line-of-sight scanning.
• Unbroken Chain of Custody: Every movement and custody change is permanently and precisionable traceable, creating a machine-readable, auditable trace trail that is inaccessible to unauthorized alteration.
• Instant Anomaly Detection: The system uses automated checks to surface exceptions immediately, such as a product appearing in an unverified location or lacking a valid history.

The primary benefit of this authentication factor is the elimination of the trust gap. By creating a unique digital twin for every physical unit, the system establishes an unbroken chain of custody that cannot be retroactively manipulated or forged. This creates a baseline of absolute truth that protects both the manufacturer and the end user.

Critically, this does not require factories to slow down or reengineer their operations. There is no need for fragile manual steps or expensive encoding processes that disrupt throughput. The system integrates into existing workflows while producing evidence that counterfeiters cannot convincingly replicate. The effect of this shift is immediate. A counterfeit item does not fail a test weeks later. It fails instantly because it lacks a valid history. A diverted product does not raise questions after the fact because the exception appears exactly when it occurs. Authenticity is no longer inferred from paperwork. It is demonstrated through data.

This changes the nature of risk management. Instead of recalls, there are blocks. Instead of explanations, there is proof. Instead of hoping partners behaved correctly, there is a shared record of what actually happened. Audits become faster, regulatory conversations become simpler, and trust is earned through data rather than assumed through contracts. Counterfeits thrive in the gaps created by ambiguity, fragmentation, and delayed verification. When every item carries its own evidence, those gaps close. This is not about better reporting. It is about building systems where the truth exists by default. Once this is achieved, counterfeits stop being a persistent threat and start becoming something supply chains can actually control.